Many here would have people thinking our management is terrible here. I cannot say that there may not have been better ways to operate, but I believe that with approval of our vaccine management will have proven to be very successful for the company, and it's investors. Perhaps they could have been more open about their goals, and if they had perhaps some long term investors would have chosen not to be, but in reality with the limited funds they're working with, it's doubtful that the job could have been done much quicker.
I believe the company recognized the need for a device like FlaskWorks to truly commercialize the vaccine and at that point found and worked to develop it knowing the trial would be concluded before the FlaskWorks unit could possibly be approved, yet they kept development going on all fronts. I don't know if everything will come together in six months, a year, or more, but when it all comes together the company will be in a position for the technology to truly be a new paradigm in the treatment of solid cancers. It won't happen overnight, but once it's available I believe you'll see off label use in many patients and if the feedback from this use is positive, our DCVax's will be found in the treatment of virtually millions of patients annually. The revenue created by such treatment could easily be as great as found in many of the BP's today. I certainly can't say NWBO will remain independent at that time, but if it is it will be trading at three to four digit prices and one of the greatest investment successes. It's easy to criticize management, but we need to realize that they've taken the company through the worst part of the journey successfully, once we have the availability of the FlaskWorks units for commercial production it ought to be smooth sailing from here on.
Gary
